Compugen and Teva Pharmaceutical will work together to discover biomarkers for the detection of drug toxicity in preclinical stages of the development process.
Initial focus of the collaboration will be on biomarkers for the early detection of potential nephrotoxicity. The parties may jointly choose to expand the scope of the partnership to include biomarkers for the detection of hepatotoxicity and/or cardiotoxicity in response to drug treatment.
Compugen has granted Teva a license to use the discovered markers for R&D activities while retaining commercialization rights for licensing them to other companies as well as rights for internal use.
Compugen expects to utilize its computational tools, discovery engines, and nucleic-acid-testing technologies for the purpose of predicting and validating toxicity biomarkers. This analysis will incorporate data derived from biological samples collected by Teva in a preclinical study designed specifically for this project as well as Compugen’s expression and clinical data.